Clinical Research Directory

Inclusion Criteria: * Type 2 diabetes mellitus diagnosed through either HbA1c ≥6,5% but ≤8,5%, or \<6,5% combined with either fasting plasma glucose ≥7,0 mmol/L or plasma glucose ≥11,1 mmol/L two hours after an oral glucose tolerance test (OGTT). * Estimated glomerular filtration rate (eGFR, CKD-EPI) between 30-60 mL/min/1.73m2 * Urine Albumin:Creatinine ratio (UACR) ≥30mg/g * Stable RAAS blockade (ACE inhibitors or angiotensin II receptor blocker (ARB) with stable dosis for 4 weeks prior to screening) * Discontinuation of treatment with selective sodium glucose transporter inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP-4i), GLP-1R analogs, rapid-acting and mix insulin 30 days before screening. Exclusion Criteria: * Immunosuppressive therapy within 30 days of screening * Alcohol abuse * Medical treatment with glucocorticoids * Kidney transplantation * Treatment for renal failure with dialysis * Myocardial infarction within 3 months of screening * Heart failure (NYHA 3-4) * Dysregulated arterial hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥ 100 mm Hg) * Liver disease (ALAT \>2 x normal value) * Conditions which may interfere with the glucose metabolism according to the PI * Severe claustrophobia * Elements incompatible with MRI * Abnormal kidney size and/or position * Venous and arterial anatomy hindering catheterization.